Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators. The US Food and Drug ...

Humira's possible elimination from the top 10 list this year is ... Dupixent from Regeneron and Sanofi is set to bring in $13.5B this year, up from $11.6B in 2023. The drug is set to gain from ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Recommended Reading Sanofi's Bioverativ deal begins to pay dividends with first new drug approval Over the past decade, the medicine Enjaymo has been passed around no less than five times by ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...